Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Paracetamol + codeine is a fixed-dose combination analgesic containing paracetamol (also known as acetaminophen) and the opioid analgesic codeine phosphate. It is used for the relief of mild to moderate pain when treatment with paracetamol or non-steroidal anti-inflammatory drugs alone is insufficient[5][8]. Paracetamol acts centrally to inhibit prostaglandin synthesis, reducing pain and fever, while codeine acts on the central nervous system as a weak opioid agonist at mu-opioid receptors, providing additional analgesia[1][3][5]. The combination offers greater pain relief than either agent alone, particularly in postoperative settings[8]. Prolonged use of codeine can lead to dependence; paracetamol overdose can cause severe liver damage[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Paracetamol + codeine.